“…Among the 36 experimental biomarkers listed in Table 1, the following biomarkers have been shown to have some degree of clinical sensitivity and specificity to PE when compared to BP and/or proteinuria and could be of interest for future PE screening tests: 1) eight blood biomarkers consisting of CA-125 [32], C-terminal GRP78 [35], HSD17B1 [39], NGAL [55], plasma factor VII [50], serum uric acid (UA) [53], sFlt1-14 [56], and soluble ST2 [54] 2) five urine markers consisting of KIM-1 [43], NGAL [43], podocyturia [48], inositol [40], and MDA [44]. Another 10 blood experimental biomarkers (AT-1AA [31], calcyclin, copeptin [34], galectin-1 [36], Gas6 [37], HIF-1aOH [38], IGFALS [41], mammalian HtrA3 [45], NT-proBNP [47], and PTX3 [49]), and four urine ones (C5b-9 [33], nephrin [46], iodine [42], and prolactin [52]) had limited clinical evaluation information, which impeded the evaluation of their performance for the diagnosis of PE.…”